Evogene Ltd. (NASDAQ:EVGN)
| Market Cap | $2.72M-72.5% |
| Revenue (ttm) | $1.14M-78.4% |
| Net Income | -$15.80M-474.8% |
| EPS | -$1.52-205.7% |
| Shares Out | 8.62M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 62,775 |
| Open | $0.33 |
| Previous Close | $0.31 |
| Day's Range | $0.30 - $0.33 |
| 52-Week Range | $0.25 - $1.26 |
| Beta | 0.68 |
| Analysts | Buy |
| Price Target | $2.15(+579.95%) |
| Earnings Date | Mar 4, 2027 |
About EVGN
Evogene Ltd. is a computational biology firm specializing in the identification and advancement of products across human health and agricultural sectors. Its proprietary Computational Predictive Biology (CPB) platform leverages deep biological insights, big data, and artificial intelligence to precisely uncover and guide the creation of life science solutions, including novel microbes, small molecules, and genetic components. The company operates through distinct divisions: Agriculture, Human Health, and Industrial Applications. The Agriculture division concentrates on improving crop performance through the development of advanced seed traits, agricultural chemicals, and biological products for crops like corn, soybean, wheat, rice, and cotton. The Human Health division focuses on pioneering microbiome-based treatments for conditions such as immuno-oncology, gastrointestinal ailments, and antibiotic-resistant infections, and also offers medical cannabis products. The Industrial Applications segment is dedicated to developing improved castor bean varieties for various industrial feedstock requirements. Evogene has a global footprint, conducting business in the United States, Israel, Brazil, and other international markets. It maintains significant partnerships, including agricultural collaborations with BASF SE, Corteva, and Bayer, and a medical cannabis development agreement with Cannbit Ltd. through its subsidiary, Canonic Ltd. Established in 1999, Evogene Ltd. is headquartered in Rehovot, Israel.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Next catalysts
- Mar 4, 2027Earnings report
$EVGN stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in EVGN holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by EVGN's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
EVGN Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New EVGN patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to EVGN from public contracts
Source: USAspending.gov
Bull Case vs Bear Case
AI-generated from EVGN’s recent data — informational, not investment advice
What’s Behind the Score
News check: Q3 2026 earnings with progress in development programs and AgPlenus fungicide advances support moderately positive sentiment, tempered by valuation concerns.
